PharmaPoint: Heart Failure – Global Drug Forecast and Market Analysis to 2026
Summary
Heart failure (HF) is a universal condition affecting people of all ages, but which is found most frequently in those over the age of 65 years. Although HF is manageable and significant breakthroughs in the treatment of chronic HF have been made in the past few decades, the condition still carries a poorer prognosis and quality of life than certain types of cancers. Moreover, the prevalence of HF is on the rise due to the aging global population; the increased prevalence of diabetes, obesity, and hypertension; and improved treatment and survival after myocardial infarction (MI).
It is estimated that the sales of HF therapeutics to be approximately US$3.7B across the 7MM in 2016. By 2026, the HF market expects to grow at a strong Compound Annual Growth Rate (CAGR) of 15.7%, reaching sales of US$16.1B by the end of the forecast period. Chronic HF therapeutics accounted for 95.9% of the total HF market in 2015, and despite the launch of a new acute HF therapy, this figure is expected to increase slightly to 98.7% by 2026. Novartis’ Entresto will be the strongest driver of the chronic HF and total HF markets in the 7MM, reaching peak sales of US$8.6B in 2022.
Major drivers of HF market growth over the forecast period are the –
– Launch of Novartis’ first-in-class angiotensin receptor-neprilysin inhibitor (ARNi), Entresto, in the US in 2015, 5EU in 2016, and Japan in 2020, significantly boosting market growth.
– Launch of several chronic HF add-on therapies, including Amgen and Cytokinetics’ omecamtiv mecarbil.
– Increase in the global prevalence of chronic HF and in the incidence of acute HF.
The 7MM chronic HF market size in 2016 was US$3.6B, and is expected to increase to US$15.6B by 2026 at a CAGR of 16.1%. The US was the largest market for chronic HF therapies, contributing 73.4% of total sales in the base year.
The report “PharmaPoint: Heart Failure – Global Drug Forecast and Market Analysis to 2026” provides a detailed analysis of the current HF market and indicates how it will evolve over the next decade following the launch of several new therapies. Moreover, it also highlights the major unmet needs in the HF space and provides strategic insights into how drug developers can target these lucrative opportunities.
Specifically, this report enables the following –
– Overview of HF, both chronic and acute, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
– Annualized HF therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the chronic and acute HF therapeutics markets.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
– Analysis of the current and future market competition in the global HF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Companies mentioned in this report: Amgen, Bayer, BMS, Cardiorentis, Cytokinetics, Les Laboratoires Servier, Merck & Co., Novartis, Ono Pharmaceuticals, Pfizer.
Scope
– Overview of HF, both chronic and acute, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
– Annualized HF therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the chronic and acute HF therapeutics markets.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
– Analysis of the current and future market competition in the global HF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
– Develop business strategies by understanding the trends shaping and driving the HF therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HF therapeutics market in future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Track drug sales in the 7MM HF therapeutics market from 2016-2026.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.